BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 33902654)

  • 1. Mitochondrial complex I abnormalities is associated with tau and clinical symptoms in mild Alzheimer's disease.
    Terada T; Therriault J; Kang MSP; Savard M; Pascoal TA; Lussier F; Tissot C; Wang YT; Benedet A; Matsudaira T; Bunai T; Obi T; Tsukada H; Ouchi Y; Rosa-Neto P
    Mol Neurodegener; 2021 Apr; 16(1):28. PubMed ID: 33902654
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Amyloid and Tau Positron Emission Tomography in Suggested Diabetesrelated Dementia.
    Takenoshita N; Fukasawa R; Ogawa Y; Shimizu S; Umahara T; Ishii K; Shimada H; Higuchi M; Suhara T; Hanyu H
    Curr Alzheimer Res; 2018; 15(11):1062-1069. PubMed ID: 29984653
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mitochondrial complex I abnormalities underlie neurodegeneration and cognitive decline in Alzheimer's disease.
    Terada T; Therriault J; Kang MS; Savard M; Pascoal TA; Lussier F; Tissot C; Wang YT; Benedet A; Poltronetti NM; Ottoy J; Arias JF; Bezgin G; Matsudaira T; Bunai T; Obi T; Tsukada H; Ouchi Y; Rosa-Neto P
    Eur J Neurol; 2022 May; 29(5):1324-1334. PubMed ID: 35007366
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Associations between quantitative [
    Timmers T; Ossenkoppele R; Wolters EE; Verfaillie SCJ; Visser D; Golla SSV; Barkhof F; Scheltens P; Boellaard R; van der Flier WM; van Berckel BNM
    Alzheimers Res Ther; 2019 Jul; 11(1):60. PubMed ID: 31272512
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tau pathology and neurodegeneration contribute to cognitive impairment in Alzheimer's disease.
    Bejanin A; Schonhaut DR; La Joie R; Kramer JH; Baker SL; Sosa N; Ayakta N; Cantwell A; Janabi M; Lauriola M; O'Neil JP; Gorno-Tempini ML; Miller ZA; Rosen HJ; Miller BL; Jagust WJ; Rabinovici GD
    Brain; 2017 Dec; 140(12):3286-3300. PubMed ID: 29053874
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vivo direct relation of tau pathology with neuroinflammation in early Alzheimer's disease.
    Terada T; Yokokura M; Obi T; Bunai T; Yoshikawa E; Ando I; Shimada H; Suhara T; Higuchi M; Ouchi Y
    J Neurol; 2019 Sep; 266(9):2186-2196. PubMed ID: 31139959
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Longitudinal 18F-MK-6240 tau tangles accumulation follows Braak stages.
    Pascoal TA; Benedet AL; Tudorascu DL; Therriault J; Mathotaarachchi S; Savard M; Lussier FZ; Tissot C; Chamoun M; Kang MS; Stevenson J; Massarweh G; Guiot MC; Soucy JP; Gauthier S; Rosa-Neto P
    Brain; 2021 Dec; 144(11):3517-3528. PubMed ID: 34515754
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association Between Amyloid and Tau Accumulation in Young Adults With Autosomal Dominant Alzheimer Disease.
    Quiroz YT; Sperling RA; Norton DJ; Baena A; Arboleda-Velasquez JF; Cosio D; Schultz A; Lapoint M; Guzman-Velez E; Miller JB; Kim LA; Chen K; Tariot PN; Lopera F; Reiman EM; Johnson KA
    JAMA Neurol; 2018 May; 75(5):548-556. PubMed ID: 29435558
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dual tracer tau PET imaging reveals different molecular targets for
    Chiotis K; Stenkrona P; Almkvist O; Stepanov V; Ferreira D; Arakawa R; Takano A; Westman E; Varrone A; Okamura N; Shimada H; Higuchi M; Halldin C; Nordberg A
    Eur J Nucl Med Mol Imaging; 2018 Jul; 45(9):1605-1617. PubMed ID: 29752516
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of qualitative and quantitative imaging characteristics of [11C]PiB and [18F]flutemetamol in normal control and Alzheimer's subjects.
    Mountz JM; Laymon CM; Cohen AD; Zhang Z; Price JC; Boudhar S; McDade E; Aizenstein HJ; Klunk WE; Mathis CA
    Neuroimage Clin; 2015; 9():592-8. PubMed ID: 26640770
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pittsburgh Compound B and AV-1451 positron emission tomography assessment of molecular pathologies of Alzheimer's disease in progressive supranuclear palsy.
    Whitwell JL; Ahlskog JE; Tosakulwong N; Senjem ML; Spychalla AJ; Petersen RC; Jack CR; Lowe VJ; Josephs KA
    Parkinsonism Relat Disord; 2018 Mar; 48():3-9. PubMed ID: 29254665
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Parallel ICA of FDG-PET and PiB-PET in three conditions with underlying Alzheimer's pathology.
    Laforce R; Tosun D; Ghosh P; Lehmann M; Madison CM; Weiner MW; Miller BL; Jagust WJ; Rabinovici GD
    Neuroimage Clin; 2014; 4():508-16. PubMed ID: 24818077
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patterns of Distribution of 18F-THK5351 Positron Emission Tomography in Alzheimer's Disease Continuum.
    Nihashi T; Sakurai K; Kato T; Iwata K; Kimura Y; Ikenuma H; Yamaoka A; Takeda A; Arahata Y; Washimi Y; Suzuki K; Bundo M; Sakurai T; Okamura N; Yanai K; Ito K; Nakamura A;
    J Alzheimers Dis; 2022; 85(1):223-234. PubMed ID: 34776443
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparing α7 nicotinic acetylcholine receptor binding, amyloid-β deposition, and mitochondria complex-I function in living brain: A PET study in aged monkeys.
    Nishiyama S; Ohba H; Kanazawa M; Kakiuchi T; Tsukada H
    Synapse; 2015 Oct; 69(10):475-83. PubMed ID: 26234533
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quantitative longitudinal interrelationships between brain metabolism and amyloid deposition during a 2-year follow-up in patients with early Alzheimer's disease.
    Förster S; Yousefi BH; Wester HJ; Klupp E; Rominger A; Förstl H; Kurz A; Grimmer T; Drzezga A
    Eur J Nucl Med Mol Imaging; 2012 Dec; 39(12):1927-36. PubMed ID: 22926714
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Associations of quantitative susceptibility mapping with Alzheimer's disease clinical and imaging markers.
    Cogswell PM; Wiste HJ; Senjem ML; Gunter JL; Weigand SD; Schwarz CG; Arani A; Therneau TM; Lowe VJ; Knopman DS; Botha H; Graff-Radford J; Jones DT; Kantarci K; Vemuri P; Boeve BF; Mielke MM; Petersen RC; Jack CR
    Neuroimage; 2021 Jan; 224():117433. PubMed ID: 33035667
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Head-to-head comparison of 11C-PiB and 18F-FC119S for Aβ imaging in healthy subjects, mild cognitive impairment patients, and Alzheimer's disease patients.
    Byun BH; Kim BI; Park SY; Ko IO; Lee KC; Kim KM; Kim YK; Lee JY; Bu SH; Kim JH; Chi DY; Ha JH; Lim SM
    Medicine (Baltimore); 2017 Mar; 96(12):e6441. PubMed ID: 28328855
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of
    La Joie R; Visani AV; Lesman-Segev OH; Baker SL; Edwards L; Iaccarino L; Soleimani-Meigooni DN; Mellinger T; Janabi M; Miller ZA; Perry DC; Pham J; Strom A; Gorno-Tempini ML; Rosen HJ; Miller BL; Jagust WJ; Rabinovici GD
    Neurology; 2021 Feb; 96(5):e650-e661. PubMed ID: 33262228
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Imaging of amyloid deposition in human brain using positron emission tomography and [18F]FACT: comparison with [11C]PIB.
    Ito H; Shinotoh H; Shimada H; Miyoshi M; Yanai K; Okamura N; Takano H; Takahashi H; Arakawa R; Kodaka F; Ono M; Eguchi Y; Higuchi M; Fukumura T; Suhara T
    Eur J Nucl Med Mol Imaging; 2014 Apr; 41(4):745-54. PubMed ID: 24233004
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of novel PET probes, [18F]BCPP-EF, [18F]BCPP-BF, and [11C]BCPP-EM for mitochondrial complex 1 imaging in the living brain.
    Harada N; Nishiyama S; Kanazawa M; Tsukada H
    J Labelled Comp Radiopharm; 2013 Sep; 56(11):553-61. PubMed ID: 24285187
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.